Key result
Transfemoral transcatheter tricuspid valve replacement resulted in near-complete elimination of tricuspid regurgitation and clinical recovery in a patient with refractory right ventricular failure.
Why the study?
Severe tricuspid regurgitation in patients with durable LVADs increases morbidity and mortality, but the role of transcatheter interventions remains limited.
Does transfemoral transcatheter tricuspid valve replacement (TTVR) improve severe tricuspid regurgitation and clinical recovery in a patient with refractory right ventricular failure post-LVAD implantation?
Case Report (n=1)
Does transfemoral transcatheter tricuspid valve replacement (TTVR) improve severe tricuspid regurgitation and clinical recovery in a patient with refractory right ventricular failure post-LVAD implantation?
Transcatheter tricuspid valve replacement offers a definitive alternative for post-LVAD severe tricuspid regurgitation when surgical repair is not feasible.
BACKGROUND: The presence of severe tricuspid regurgitation (TR) in patients supported with durable left ventricular assist devices (LVADs) is associated with increased morbidity and mortality. The role of transcatheter interventions remains limited, but represents a promising therapeutic frontier. CASE SUMMARY: A 62-year-old woman with chemotherapy-induced cardiomyopathy underwent HeartMate 3 LVAD implantation, complicated by progressive right ventricular (RV) dilation, severe annular dilation, and torrential secondary TR with marked leaflet malcoaptation. Despite guideline-directed medical therapy and chronic inotropic support, she developed refractory RV failure with a ventricularized right atrial waveform on catheterization. Given prohibitive surgical risk, transfemoral transcatheter tricuspid valve replacement (TTVR) with a 56-mm Edwards EVOQUE valve was performed, resulting in near-complete TR elimination, improved RV-pulmonary artery coupling, and clinical recovery. DISCUSSION: This case illustrates TTVR as a viable therapy for refractory TR and RV failure in select LVAD-supported patients. TAKE-HOME MESSAGE: TTVR offers a definitive alternative for post-LVAD severe TR when surgical repair is not feasible.
No takes yet. Share an insight, caveat, or question.
Giustino et al. (2026) conducted a case report in Severe tricuspid regurgitation post-LVAD (n=1). Transfemoral transcatheter tricuspid valve replacement (TTVR) was evaluated on Tricuspid regurgitation elimination and clinical recovery. Transfemoral transcatheter tricuspid valve replacement resulted in near-complete elimination of tricuspid regurgitation and clinical recovery in a patient with refractory right ventricular failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: